OBALON THERAPEUTICS INC Contracts & Agreements

Form of Pre-Funded Warrant to purchase shares of Common Stock, dated December 19, 2024 (Filed With SEC on December 20, 2024)

Equity Purchase Agreement, dated as of December 19, 2024, by and between the Company and Ascent (Filed With SEC on December 20, 2024)

Form of Securities Purchase Agreement, dated as of October 16, 2024 by and between the Company and the Investor (Filed With SEC on October 17, 2024)

Form of Note, dated as of October 16, 2024 (Filed With SEC on October 17, 2024)

Form of Registration Rights Agreement, dated as of October 16, 2024 by and between the Company and the Investor (Filed With SEC on October 17, 2024)

Form of Security Agreement, dated October 16, 2024 (Filed With SEC on October 17, 2024)

Form of Guaranty, dated October 16, 2024 (Filed With SEC on October 17, 2024)

Form of Lock-Up Agreement, dated October 16, 2024 (Filed With SEC on October 17, 2024)

Form of Leak-Out Agreement, dated October 16, 2024 (Filed With SEC on October 17, 2024)

Subsidiaries of ReShape Lifesciences Inc (Filed With SEC on October 1, 2024)

Employment Agreement dated September 30, 2019 between Vyome Therapeutics, Inc. and Venkateswarlu Nelabhotla (Filed With SEC on October 1, 2024)

Employment Letter dated June 27, 2024 between Vyome Therapeutics, Inc. and Frank Wisner (Filed With SEC on October 1, 2024)

Consulting Agreement dated August 26, 2024 between Vyome Therapeutics, Inc. and Foresite Advisors, LLC (Filed With SEC on October 1, 2024)

Lease Agreement dated January 1, 2024 between Sita Gupta and Vyome Therapeutics Limited for the property located at ground floor, Industrial Property no. 465, FIE, Patparganj, New... (Filed With SEC on October 1, 2024)

Lease Agreement dated January 1, 2024 between Sita Gupta and Vyome Therapeutics Limited for the property located at basement floor, Industrial Property no. 465, FIE, Patparganj,... (Filed With SEC on October 1, 2024)

Lease Agreement dated October 1, 2022 between Neeta Jain and Vyome Therapeutics Limited for the property located at C-4/201, Akshar Pavillion, Vadodara – 390021, India (Filed With SEC on October 1, 2024)

Lease Extension Letter dated September 5, 2023 between Neeta Jain and Vyome Therapeutics Limited for the property located at C-4/201, Akshar Pavillion, Vadodara – 390021, India (Filed With SEC on October 1, 2024)

Agreement and Plan of Merger, dated as of July 8, 2024, by and among ReShape Lifesciences Inc., Vyome Therapeutics, Inc., and Raider Lifesciences Inc (Filed With SEC on July 9, 2024)

Asset Purchase Agreement, dated as of July 8, 2024, by and between ReShape Lifesciences Inc. and Ninjour Health International Limited (Filed With SEC on July 9, 2024)

Agreement to Amend Series C Convertible Preferred Stock, dated as of July 8, 2024, by and among ReShape Lifesciences Inc. and holders of Series C Convertible Preferred Stock (Filed With SEC on July 9, 2024)

Form of Subscription Agreement by and between ReShape Lifesciences Inc. and the investors party thereto (Filed With SEC on July 9, 2024)

Form of Voting and Support Agreement by and among ReShape Lifesciences Inc. and certain stockholders of Vyome Therapeutics, Inc (Filed With SEC on July 9, 2024)

Amendment to Employment Agreement, dated July 8, 2024, by and between ReShape Lifesciences Inc. and Paul F. Hickey (Filed With SEC on July 9, 2024)

Executive Employment Agreement, dated October 29, 2019, by and between the Company and Thomas Stankovich (Filed With SEC on April 1, 2024)

Form of New Warrant (Filed With SEC on November 29, 2023)

Form of Warrant Exercise Agreement, dated November 21, 2023, by and between ReShape Lifesciences Inc. and the Investor (Filed With SEC on November 29, 2023)

Form of Placement Agent Warrant (Filed With SEC on October 5, 2023)

Form of Common Warrant (Filed With SEC on September 27, 2023)

Exclusive License Agreement, dated September 19, 2023, by and between ReShape Lifesciences Inc. and Biorad Medysis Pvt. Ltd (Filed With SEC on September 22, 2023)

Form of Placement Agency Agreement (Filed With SEC on September 12, 2023)

Form of Common Warrant (Filed With SEC on September 12, 2023)

Form of Pre-Funded Warrant (Filed With SEC on September 12, 2023)

Form of Securities Purchase Agreement (Filed With SEC on September 12, 2023)

Form of Common Stock Purchase Warrant (Filed With SEC on April 26, 2023)

Form of Pre-funded Warrant (Filed With SEC on April 26, 2023)

Form of Securities Purchase Agreement, dated April 20, 2023, by and between ReShape Lifesciences Inc. and the Investor (Filed With SEC on April 26, 2023)

Executive Employment Agreement, dated October 29, 2019, by and between the Company and Thomas Stankovich (Filed With SEC on April 17, 2023)

Underwriting Agreement, dated February 6, 2023, by and between ReShape Lifesciences Inc. and Maxim Group LLC (Filed With SEC on February 10, 2023)

Form of Common Warrant (Filed With SEC on February 3, 2023)

Form of Underwriting Agreement (Filed With SEC on January 27, 2023)

Form of Common Warrant (Filed With SEC on January 27, 2023)

Form of Pre-Funded Warrant (Filed With SEC on January 27, 2023)

Form of Underwriters Warrant (Filed With SEC on January 27, 2023)

Form of Warrant Agency Agreement between ReShape and American Stock Transfer & Trust Company, LLC (Filed With SEC on January 27, 2023)

ReShape Lifesciences Inc. 2022 Equity Incentive Plan (Filed With SEC on December 20, 2022)

Employment Agreement, dated November 1, 2022, between the Company and Paul F. Hickey (Filed With SEC on November 14, 2022)

Form of Common Stock Purchase Warrant (Filed With SEC on November 14, 2022)

Form of Pre-funded Warrant (Filed With SEC on November 14, 2022)

Form of Securities Purchase Agreement, dated November 8, 2022, by and between ReShape Lifesciences Inc. and the Investor (Filed With SEC on November 14, 2022)

Form of Warrant Amendment Agreement, dated November 8, 2022, by and between ReShape Lifesciences Inc. and the Investor (Filed With SEC on November 14, 2022)

Offer Letter, dated July 25, 2022, by and between the Company and Paul Hickey (Filed With SEC on August 2, 2022)

Retention Bonus Agreement, dated August 2, 2022, by and between the Company and Thomas Stankovich (Filed With SEC on August 2, 2022)

Form of New Warrant (Filed With SEC on June 23, 2022)

Warrant Exercise Agreement, dated June 16, 2022, by and among ReShape Lifesciences Inc. and the investor party thereto (Filed With SEC on June 23, 2022)

Description of Registrants Securities (Filed With SEC on April 8, 2022)

Executive Employment Agreement, dated August 26, 2019, by and between the Company and Barton P. Bandy (Filed With SEC on April 8, 2022)

Executive Employment Agreement, dated October 29, 2019, by and between the Company and Thomas Stankovich (Filed With SEC on April 8, 2022)

Form of New Warrant (Filed With SEC on July 19, 2021)

Form of Exchange Agreement, dated July 16, 2021, by and among ReShape Lifesciences Inc. and the investors party thereto (Filed With SEC on July 19, 2021)

Form of New Warrant (Filed With SEC on July 2, 2021)

Warrant Exercise Agreement, dated June 28, 2021, by and among ReShape Lifesciences Inc. and the purchasers party thereto (Filed With SEC on July 2, 2021)

Second Amended and Restated 2003 Stock Incentive Plan of ReShape Lifesciences Inc., as amended on May 23, 2018 (Filed With SEC on March 30, 2021)

Form of Stock Option Grant Notice and Stock Option Agreement under ReShape Lifesciences Inc.s Second Amended and Restated 2003 Stock Incentive Plan (Filed With SEC on March 30, 2021)

Executive Employment Agreement, dated as of May 22, 2017, by and between ReShape Lifesciences Inc. and Dr. Raj Nihalani (Filed With SEC on March 30, 2021)

Lease agreement, entered into January 20, 2017, by and between ReShape Medical, Inc. and San Clemente Holdings, LLC (Filed With SEC on March 30, 2021)

Credit Agreement, dated March 25, 2020, by and between ReShape Lifesciences Inc. and Armistice Capital Master Fund Ltd (Filed With SEC on March 30, 2021)

Guarantee and Collateral Agreement, dated March 25, 2020, by and between ReShape Lifesciences Inc., ReShape Medical LLC and Armistice Capital Master Fund Ltd (Filed With SEC on March 30, 2021)

Second Amendment to Credit Agreement, dated September 14, 2020, by and between ReShape Lifesciences Inc. and Armistice Capital Master Fund Ltd (Filed With SEC on March 30, 2021)

Third Amendment to Credit Agreement, dated December 16, 2020, by and between ReShape Lifesciences Inc. and Armistice Capital Master Fund Ltd (Filed With SEC on March 30, 2021)

Credit Facility Agreement, dated as of January 19, 2021, by and between ReShape Lifesciences Inc. and Armistice Capital Master Fund Ltd (Filed With SEC on March 30, 2021)

Fourth Amendment to Credit Agreement, dated January 19, 2021, by and between ReShape Lifesciences Inc. and Armistice Capital Master Fund Ltd (Filed With SEC on March 30, 2021)

Executive Employment Agreement, dated as of August 26, 2019, by and between ReShape Lifesciences Inc. and Barton Bandy (Filed With SEC on March 30, 2021)

Employment Agreement, dated as of October 29, 2019, by and between ReShape Lifesciences Inc. and Thomas Stankovich (Filed With SEC on March 30, 2021)

Amendment and Restated Retention Agreement, dated as of January 18, 2021, by and between Obalon Therapeutics, Inc. and Andrew Rasdal (Filed With SEC on March 12, 2021)

Amendment to Amended and Restated Retention Agreement, dated as of January 18, 2021, by and between Obalon Therapeutics, Inc. and Nooshin Hussainy (Filed With SEC on March 12, 2021)

Agreement and Plan of Merger, dated as of January 19, 2021, by and among Obalon Therapeutics, Inc., Optimus Merger Sub, Inc., and ReShape Lifesciences Inc (Filed With SEC on January 20, 2021)

Amended and Restated 2016 Equity Incentive Plan and form award agreements thereunder (Filed With SEC on November 6, 2020)

Form of Warrant (Filed With SEC on August 14, 2020)

Consulting Agreement, dated August 11, 2020, between the Company and Blue Ox Healthcare Partners, LLC (Filed With SEC on August 14, 2020)

Form of Stock Option Agreement (Cash Settlement) (Filed With SEC on July 30, 2020)

Amended and Restated Retention Agreement, dated as of June 9, 2020, by and between Obalon Therapeutics, Inc. and Andrew Rasdal (Filed With SEC on June 19, 2020)

Amended and Restated Retention Agreement, dated as of June 9, 2020, by and between Obalon Therapeutics, Inc. and Nooshin Hussainy (Filed With SEC on June 19, 2020)

Transition and Consulting Agreement, dated as of June 11, 2020, by and between Obalon Therapeutics, Inc. and Amy Vandenberg (Filed With SEC on June 19, 2020)

Transition and Consulting Agreement, dated as of June 11, 2020, by and between Obalon Therapeutics, Inc. and Mark Brister (Filed With SEC on June 19, 2020)

Promissory Note, dated as of April 22, 2020 by and between Obalon Therapeutics, Inc. and Silicon Valley Bank (Filed With SEC on April 27, 2020)

Description of Registrant's Securities (Filed With SEC on February 27, 2020)

Form of Restricted Stock Unit Award pursuant to the 2016 Equity Incentive Plan (Filed With SEC on February 27, 2020)

Form of Restricted Stock Unit Award Agreement (Share and Cash Settlement) pursuant to the 2016 Equity Incentive Plan (Filed With SEC on February 27, 2020)

Purchase Agreement, dated February 5, 2020, by and between the Company and Lincoln Park Capital Fund, LLC (Filed With SEC on February 7, 2020)

Registration Rights Agreement, dated February 5, 2020, by and between the Company and Lincoln Park Capital Fund, LLC (Filed With SEC on February 7, 2020)

Offer Letter dated November 15, 2011 between the Company and Nooshin Hussainy (Filed With SEC on February 7, 2020)

Underwriting Agreement, entered into by Obalon Therapeutics, Inc. on August 1, 2019 with A.G.P./Alliance Global Partners (Filed With SEC on August 6, 2019)

Form of Underwriting Agreement (Filed With SEC on August 1, 2019)

Form of Pre-Funded Warrant (Filed With SEC on August 1, 2019)

Form of Common Stock Purchase Warrant (Filed With SEC on August 1, 2019)

Form of Warrant Agent Agreement between Obalon Therapeutics, Inc. and American Stock Transfer & Trust Company, LLC (Filed With SEC on August 1, 2019)

Form of Underwriting Agreement (Filed With SEC on July 30, 2019)

Consulting Agreement dated May 20, 2019 between the Company and Kelly Huang (Filed With SEC on July 24, 2019)

Offer Letter dated May 26, 2019 between the Company and Robert MacDonald (Filed With SEC on July 24, 2019)

Form of Securities Purchase Agreement (Filed With SEC on May 28, 2019)

First Amendment to 2016 Equity Incentive Plan (Filed With SEC on February 22, 2019)

Form of Restricted Stock Unit Award pursuant to the 2016 Equity Incentive Plan (Filed With SEC on February 22, 2019)

Equity Distribution Agreement, dated December 27, 2018, between Obalon Therapeutics, Inc. and Canaccord Genuity LLC (Filed With SEC on December 27, 2018)

Purchase Agreement, dated December 27, 2018, by and between the Company and Lincoln Park Capital Fund, LLC (Filed With SEC on December 27, 2018)

Registration Rights Agreement, dated December 27, 2018, by and between the Company and Lincoln Park Capital Fund, LLC (Filed With SEC on December 27, 2018)

Fifth Amendment to Loan and Security Agreement (Filed With SEC on August 2, 2018)

Fourth Amendment to Lease dated May 31, 2018 between Gildred Development Company, DBA Ocean Point and Obalon Therapeutics Inc (Filed With SEC on June 5, 2018)

Form of Executive Retention Agreement (Non-CEO) (April 2018) (Filed With SEC on May 10, 2018)

Amendment to Obalon Therapeutics, Inc. 2016 Employee Stock Purchase Plan (Filed With SEC on May 4, 2018)

Offer Letter dated August 14, 2017 between the Company and Kelly Huang (Filed With SEC on March 5, 2018)

FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (Filed With SEC on August 2, 2017)

OBALON THERAPEUTICS, INC. DIRECTOR COMPENSATION PROGRAM (EFFECTIVE APRIL 24, 2017) (Filed With SEC on August 2, 2017)

APPENDIX (Filed With SEC on May 10, 2017)

NOTICE OF STOCK OPTION GRANT OBALON THERAPEUTICS INC. 2016 EQUITY INCENTIVE PLAN (Filed With SEC on February 23, 2017)

TERM (Filed With SEC on February 23, 2017)

THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT (Filed With SEC on February 23, 2017)

Retention Agreement (Filed With SEC on November 10, 2016)

OBALON THERAPEUTICS, INC. [ ] Shares Common Stock ($0.001 par valueper Share) UNDERWRITING AGREEMENT (Filed With SEC on September 26, 2016)

INDEMNITY AGREEMENT (Filed With SEC on September 26, 2016)

OBALON THERAPEUTICS, INC. 2016 EQUITY INCENTIVE PLAN (Filed With SEC on September 26, 2016)

OBALON THERAPEUTICS, INC. 2016 EMPLOYEE STOCK PURCHASE PLAN (Filed With SEC on September 26, 2016)

DISTRIBUTION AGREEMENT (Filed With SEC on September 26, 2016)

OBALON THERAPEUTICS, INC. BONUS PLAN (Filed With SEC on September 26, 2016)

RETENTION AGREEMENT (Filed With SEC on September 26, 2016)

Additional abbreviations mayalso be used though not in the above list. (Filed With SEC on September 9, 2016)

FOURTH AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT (Filed With SEC on September 9, 2016)

OBALON THERAPEUTICS, INC. PREFERRED STOCK PURCHASE WARRANT (Filed With SEC on September 9, 2016)

AMENDED AND RESTATED WARRANT TO PURCHASE STOCK (Filed With SEC on September 9, 2016)

SECOND WARRANT TO PURCHASE STOCK (Filed With SEC on September 9, 2016)

THIRD WARRANT TO PURCHASE STOCK (Filed With SEC on September 9, 2016)

OBALON THERAPEUTICS, INC. 2008 STOCK PLAN (Filed With SEC on September 9, 2016)

AIR COMMERCIAL REAL ESTATE ASSOCIATION STANDARD INDUSTRIAL/COMMERCIAL MULTI-TENANT LEASE GROSS (Filed With SEC on September 9, 2016)

DISTRIBUTION AGREEMENT (Filed With SEC on September 9, 2016)

OBALON THERAPEUTICS, INC. OBALON THERAPEUTICS, LLC LOAN AND SECURITY AGREEMENT (Filed With SEC on September 9, 2016)

Category

Industry

Companies

Contracts

OBALON THERAPEUTICS INC Contracts & Agreements